New Drug Pipeline_Jiangsu Vcare PharmaTech Co. Ltd.,

NEW DRUG PIPELINE

Schedule

Vicagrel(P2Y12)

86%

VC004(TRK)

62%

VC005(JAK)

58%

323(Flt3)

42%

VC008(Kras)

35%

VC009(SHP2)

35%

VC010

30%

VC011

30%

VC012

30%

NEW DRUG PIPELINE

Statistical table of clinical trials of innovative drugs

创新药临床试验统计表

Time of issue:2021-04-28 08:16:49

Item	Indication/Population	Test name
VC004	NTRK-positive solid tumors	Phase I/II Clinical Trial of VC004 in Patients with Locally Advanced/Metastatic Solid Tumors
Vicagrelor	Healthy subjects	Clinical Study on Body Mass Balance and Biotransformation of [14C] Vecagrelor
Vicagrelor	Healthy subjects	Pharmacokinetic/Pharmacodynamic Studies of CYP2C19 Metabolizers
Vicagrelor	Coronary heart disease	Clinical study on the safety and efficacy of Vecagrelor in patients with coronary heart disease scheduled for PCI
Vicagrelor	Healthy subjects	Efficacy, safety and tolerability of multiple doses of Vecagrelor Tablets
Vicagrelor	Healthy subjects	Effect of Food on Vecagrelor and Loading Dose Exploration
Vicagrelor	Healthy subjects	Single Dose Escalation Tolerance Study of Vecagrelide Tablets

For more information about clinical trials of our products, please visit http://www.chinadrugtrials.org.cn/

Introduction to innovative drug project

Vicagrel

Vicagrel is an industry-university-research cooperation project between Jiangsu Vcare Pharmaceutical Technology Co., Ltd. and China Pharmaceutical University. Vcare owns the complete rights and intellectual property rights of the product. The research results of Vicagrel have been successively published in many core journals domestic and abroad, and have been recommended by the publication "SciBX" under the "Nature" publication saying vicagrel was rated as "one of the most promising projects in the field of new drugs".

As the project PI, Academician Yaling Han of Northern Theater General Hospital, Chairman of Cardiovascular Branch of Chinese Medical Association, Honorary President of Cardiovascular Physician Branch of Chinese Medical Doctor Association instructed the clinical team to complete a number of key clinical studies such as Phase II clinical trials, and gave the product a high evaluation. Vicagrel is about to start phase III clinical trials in China.

VC004

VC004 is a type 1 targeted anti-tumor drug independently developed by Vcare. It belongs to the second generation of Trk inhibitors. It is expected to provide domestic patients with a treatment for NTRK fusion mutations, while meeting the unmet clinical needs of domestic and foreign patients for anti-drug treatment.

VC004 as a new generation of therapeutic drugs, has excellent in vivo and in vitro activities, good pharmacokinetic properties, good tolerance, and outstanding clinical potential. There are no TRK inhibitor drugs on the market in China and no second-generation anti-drug inhibitor drugs on the market domestic and abroad at present, so VC004 is expected to be the world's leading second-generation TRK inhibitor.

VC005

VC005 is a new, highly effective and selective JAK1 inhibitor with intestinal restrictive effect independently developed by Vcare. It has the characteristics of controllable systemic exposure and high intestinal exposure. Pre-clinical studies have confirmed that the drug has a low effective dose, a high tolerated dose and low side effects in animals. VC005 has the dual advantages of safety and efficacy, and is expected to become the world's leading intestinal selective anti-inflammatory drug.